Pyridine

Pyridine

SCHEMBL407438

O=S(=O)(O)O.c1ccncc1

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CALCRLCHRM1CHRM2CHRM3F2RMAOAMAOBMAP2K1MAP2K2NTRK1NTRK2NTRK3OPRD1OPRK1OPRM1P2RY12PKLRSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASLC18A2SLC6A2SLC6A3TLR7TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8dacAdacBdacCfolAftsImrcAmrcBmrdApolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmB1rpmB2rpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmHrpmIrpmJrpmJ2rpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsR1rpsR2rpsSrpsTrpsUrpsZykgMykgO

The experimentally established mechanism targets of Pyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 4/20 0.60
TSHR P16473 2/20 0.60
TDP1 Q9NUW8 1/20 0.60
CA5A P35218 1/20 0.40
CA5B Q9Y2D0 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
GAA P10253 2/20 0.33
ALDH1A1 P00352 2/20 0.33
APP P05067 1/20 0.33
HCAR3 P49019 1/20 0.33
HCAR2 Q8TDS4 1/20 0.33
HPGD P15428 3/20 0.32
KDM4E B2RXH2 2/20 0.32
ALOX12 P18054 1/20 0.32
TAAR1 Q96RJ0 1/20 0.31
PLOD2 O00469 1/20 0.31
PLOD3 O60568 1/20 0.31
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL22261990 1.00 NAPRT (0.60) NAPRTTSHRTDP1CA5ACA5B
Pyridine SCHEMBL1005857 1.00 NAPRT (0.60) NAPRTTSHRTDP1CA5ACA5B
Pyridine SCHEMBL22261964 1.00 NAPRT (0.60) NAPRTTSHRTDP1CA5ACA5B
Pyridine SCHEMBL1407986 1.00 NAPRT (0.60) NAPRTTSHRTDP1CA5ACA5B
Pyridine SCHEMBL3316655 1.00 NAPRT (0.60) NAPRTTSHRTDP1CA5ACA5B
Pyridine SCHEMBL25405557 0.97 NAPRT (0.56) NAPRTTSHRTDP1CA5ACA5B
Pyridine SCHEMBL22151317 0.97 NAPRT (0.56) NAPRTTSHRTDP1CA5ACA5B
Pyridine SCHEMBL22151316 0.97 NAPRT (0.56) NAPRTTSHRTDP1CA5ACA5B
Pyridine SCHEMBL122022 0.97 NAPRT (0.56) NAPRTTSHRTDP1CA5ACA5B
Pyridine SCHEMBL11617873 0.97 NAPRT (0.56) NAPRTTSHRTDP1CA5ACA5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025245379-A1 SUPERCRITICAL FLUIDS REGENERATION OF PFAS-CONTAMINATED SPENT MEDIA AND WATER TREATMENT TRAIN UNIVERSITY OF WASHINGTON (US) 2025-11-27 WO claimed
EP-3822259-B1 METHOD FOR SYNTHESIZING VALSARTAN ZHEJIANG HUAHAI PHARM CO LTD (CN) 2025-08-27 EP claimed
US-20250207049-A1 METHOD FOR PRETREATING WASTE FAT, OIL AND GREASE AND CO-PRODUCING FIRST-GENERATION BIODIESEL FUZHOU UNIVERSITY (CN) 2025-06-26 US claimed
US-20250051311-A1 Method for Preparing High-Purity Losartan ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) 2025-02-13 US claimed
US-12180181-B1 4-[4,5-bis(4-bromophenyl)-1-hexyl-1H-imidazol-2-yl]isoquinolin-3-ol as an antimicrobial compound King Faisal University (SA) 2024-12-31 US claimed
CN-119175052-A Industrial preparation method of acrolein 中国石油化工股份有限公司 2024-12-24 CN claimed
US-12162839-B1 4,5-bis(4-bromophenyl)-2-(4-bromophenyl)-1-hexyl-1H-imidazole as an antimicrobial compound King Faisal University (SA) 2024-12-10 US claimed
CN-119019307-A Vitamin D3Is prepared by the preparation method of (2) 厦门金达威维生素有限公司 2024-11-26 CN claimed
CN-118634644-B Acrylic ester tail gas treatment method 江苏环保产业技术研究院股份公司 2024-11-08 CN claimed
US-12134604-B1 1-[4,5-bis(4-chlorophenyl)-1-hexyl-1H-imidazol-2-yl]-2-naphthol as an antimicrobial compound King Faisal University (SA) 2024-11-05 US claimed
EP-0411541-A2 Process for preparing monobactames and their intermediate product CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 1991-02-06 EP claimed
EP-0107860-B1 PEPTIDES, PROCESS FOR PREPARING THE SAME AND PSYCHODEPRESSANT COMPOSITIONS CONTAINING THE SAME AMANO PHARMACEUTICAL CO., LTD. (JP) 1986-09-17 EP claimed
US-4565811-A Sodium salt of ursodeoxycholic sulphate ISTITUTO BIOLOGICO CHEMIOTERAPICO "ABC" S.P.A. (IT) 1986-01-21 US claimed
EP-0159026-A2 Pentaerythritol derivatives and a process for preparing the same Chugai Seiyaku Kabushiki Kaisha (JP) 1985-10-23 EP claimed
EP-0117570-A1 Sodium salt of ursodeoxycholic sulphate ISTITUTO BIOLOGICO CHEMIOTERAPICO "ABC" S.p.A. (IT) 1984-09-05 EP claimed
EP-0107860-A1 Peptides, process for preparing the same and psychodepressant compositions containing the same AMANO PHARMACEUTICAL CO., LTD. (JP) 1984-05-09 EP claimed
EP-0053387-A1 Method of preparing 1-sulfo-2-oxoazetidine derivatives and intermediates therefor Takeda Chemical Industries, Ltd. (JP) 1982-06-09 EP claimed
US-4269992-A REFLUXING A POLYDIHYDROCARBON SILOXANE CONTAINING HALOGEN GROUPS AND AN ALCOHOL-MODIFIED POLYOXYALKYLENE GLYCOL IN A SOLVENT OF AN ALKYL OR ALKENYL HALIDE UNION CARBIDE CORPORATION (US) 1981-05-26 US claimed
US-4093522-A WITH WATER SOLUBLE PYRIDINIUM, QUINOLINIUM OR ACRIDINIUM SULFATE AND HALIDE DILLENBERG HORST 1978-06-06 US claimed
US-4067825-A Method for preparation of amphoteric ion-exchangers by substitution of hydrophilic polymers CESKOSLOVENSKA AKADEMIE VED (CS) 1978-01-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051311-A1 Method for Preparing High-Purity Losartan AGTR1, AGTR2, AGT NAPRT 1355/4885TSHR 1906/4885TDP1 1715/4885
US-12134604-B1 1-[4,5-bis(4-chlorophenyl)-1-hexyl-1H-imidazol-2-yl]-2-naphthol as an antimicrobial compound NOC2L, NCKAP1L, NOM1 NAPRT 372/4885TSHR 4524/4885TDP1 3458/4885
US-12180181-B1 4-[4,5-bis(4-bromophenyl)-1-hexyl-1H-imidazol-2-yl]isoquinolin-3-ol as an antimicrobial compound IRF3, IFNG, TLR4 NAPRT 2198/4885TSHR 4653/4885TDP1 4349/4885
US-12162839-B1 4,5-bis(4-bromophenyl)-2-(4-bromophenyl)-1-hexyl-1H-imidazole as an antimicrobial compound BRD4, IL4, CASP4 NAPRT 1702/4885TSHR 3702/4885TDP1 3863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.